Tehran (IP) - Head of the Razi Vaccine and Serum Research Institute says the Iranian 'Razi Cov Pars' inhaled vaccine is the first vaccine to be used via intranasal spraying in the world.

Iran PressIran News: In an interview with Iran Press on the production of inhaled 'Razi Cov Pars' vaccine, Ali Es'haqi stated: "It is too early to judge on mass production, so after the third phase's completion, the conclusion can be made."

Razi Cov Pars vaccine is done in three doses; the first two doses were injectable, and the third dose is inhaled. The volunteers are those who have gotten the first and second doses.

"We currently have two production lines, one can produce ten million doses and the other two hundred million a year," Es'haqi noted.

He pointed out that two out of the 131 volunteers had received the inhaled vaccine 51 days after receiving the two injections.

"The most important reason for COVID-19 spread was that a group of infected people who were carrying the virus showed no symptoms of the disease, so their respiratory system had to be secured; this inhaled dose activates the Immunoglobulin E (IgE) in the upper respiratory tract two weeks after the inhaling and prevents other people from being contracted," he explained.

"The second phase of the inhaled vaccination will be carried out on 500 volunteers in early June, and after two months, the third phase will start," he said.

The intranasal spray of the 'Razi Cov Pars' vaccine in phase I clinical trial was inaugurated at Tehran's Rasoul Akram Hospital on Wednesday.


Read More:

Volunteers get 'Razi Cov Pars' intranasal spray

Razi Vaccine Head: 'Cov Pars', an excellent option for corona vaccination